A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : PFS / progression-free

[Related PubMed/MEDLINE]
Total Number of Papers: 463
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   PFS  (>> Co-occurring Abbreviation)
Long Form:   progression-free
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 A new immunotherapy schedule in addition to first-line hormone therapy for metastatic breast cancer patients in a state of clinical benefit during hormone therapy. AIs, DFI, HT, OS, SERMs
2020 An international multicenter retrospective analysis of patients with extranodal marginal zone lymphoma and histologically confirmed central nervous system and dural involvement. OS
2020 Anti-EGFR Monoclonal Antibodies in Advanced Biliary Tract Cancer: A Systematic Review and Meta-analysis. BTC, CHT, EGFR, EGFR
2020 Body composition is prognostic and predictive of ipilimumab activity in metastatic melanoma. HR, HU, OS
2020 Clinical perspectives from ongoing trials in oligometastatic or oligorecurrent prostate cancer: an analysis of clinical trials registries. OS, PCa
2020 Effect of delay between nuclear medicine scanning and sentinel node biopsy on outcome in patients with cutaneous melanoma. DSS, SLNB
2020 Efficacy of Allogeneic Hematopoietic Cell Transplantation in Cutaneous T Cell Lymphoma: Results of a Systematic Review and Meta-Analysis. allo-HCT, CI, NRM
2020 Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma. BOR, OS, PD-L1
2020 Extended time interval between diagnosis and surgery does not improve the outcome in patients operated for resection or ablation of breast cancer liver metastases. BCLM, ES, LS, OS
10  2020 High total metabolic tumor volume at baseline allows discrimination of survival even in patients aged 60 to 80 years responding to R-CHOP. DLBCL, OS, TMTV
11  2020 Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma. IHC, LGSC, OS, OvCaRe
12  2020 Metabolic Tumor Volume Response Assessment Using (11)C-Methionine Positron Emission Tomography Identifies Glioblastoma Tumor Subregions That Predict Progression Better Than Baseline or Anatomic Magnetic Resonance Imaging Alone. CI, HR, MET-PET, MTV
13  2020 Neck management in patients with olfactory neuroblastoma. ENI, ONB
14  2020 Prognostic and radiographic correlates of a prospectively collected molecularly profiled cohort of IDH1/2-wildtype astrocytomas. OS, WT
15  2020 Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy. CPI, CRT, OS, TIL, TIME
16  2020 Radiotherapy for geriatric head-and-neck cancer patients: what is the value of standard treatment in the elderly? HNSCC, LRC, OS
17  2020 Sentinel lymph node mapping alone compared to more extensive lymphadenectomy in patients with uterine serous carcinoma. LND, OS, PALND, SLN, USC
18  2020 Whole brain apparent diffusion coefficient measurements correlate with survival in glioblastoma patients. ADC, GBM
19  2019 A multicenter, prospective phase II trial of gemcitabine plus axitinib in patients with renal cell carcinoma with a predominant sarcomatoid component. GX, ORR, SRCC
20  2019 Association between lymphovascular invasion and oncologic outcomes among upper urinary tract urothelial carcinoma patients who underwent radical nephroureterectomy. LVI, OS, RNU, UTUC
21  2019 Autologous Hematopoietic Stem Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 Decades. auto-HCT, CI, GCTs, OS, ST, TT
22  2019 Blood graft composition and post-transplant recovery in myeloma patients mobilized with plerixafor: a prospective multicenter study. CY, MM, OS
23  2019 Combination of Immunotherapy and Brain Radiotherapy in Metastatic Melanoma: A Retrospective Analysis. IO, MM, OS, RT
24  2019 Comparative Analysis of Subventricular Zone Glioblastoma Contact and Ventricular Entry During Resection in Predicting Dissemination, Hydrocephalus, and Survival. SVZ
25  2019 Cytosolic Hsp70 as a biomarker to predict clinical outcome in patients with glioblastoma. cHsp70, GBM, HSP70, OS
26  2019 Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome. MM, OS, RR
27  2019 Does restaging transurethral resection of bladder tumour influence outcomes in patients treated with BCG immunotherapy? 491 cases in 20 years' experience. BCG, reTURB
28  2019 Dose-intensified chemoradiation is associated with altered patterns of failure and favorable survival in patients with newly diagnosed glioblastoma. GTR, OS
29  2019 Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC-A retrospective cohort study. CA19-9, CEA, ICI, NSCLC, NSE, OS, RECIST, STM
30  2019 EBMT prospective observational study on allogeneic hematopoietic stem cell transplantation in T-prolymphocytic leukemia (T-PLL). allo-SCT, CR, T-PLL, TBI6
31  2019 Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study. CI, mTOR, OS, TRAE
32  2019 Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors. CRP, MEL, NSCLC, OS, ULN
33  2019 Expression of connective tissue growth factor as a prognostic indicator and its possible involvement in the aggressive properties of epithelial ovarian carcinoma. CTGF, EOC, OS, PTX
34  2019 EZH2 Overexpression in Multiple Myeloma: Prognostic Value, Correlation With Clinical Characteristics, and Possible Mechanisms. CI, OS
35  2019 Fibroblast growth factor receptor 4 (FGFR4) as detected by immunohistochemistry is associated with postoperative residual disease in ovarian cancer. FGFR4, HGSOC, IHC
36  2019 Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Mullerian origin. i.p, OS, Trial A
37  2019 FOXM1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non-muscle-invasive bladder cancer. CSS, FOXM1, NMIBC
38  2019 Gemcitabine, vinorelbine and dexamethasone: A safe and effective regimen for treatment of relapsed/refractory hodgkin's lymphoma. DEX, HL, OS
39  2019 High-dose etoposide could discriminate the benefit from autologous peripheral blood stem cell transplantation in the patients with refractory diffuse large B cell lymphoma. APBSCT, DLBCL, OS, PD
40  2019 Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma. irAEs
41  2019 Impact of primary disease on outcome after allogeneic stem cell transplantation for transformed secondary acute leukaemia. allo-HSCT, CMML, HLA, MDS, MPN, NRM, OS, sAML
42  2019 Impact of second decline rate of BCR-ABL1 transcript on clinical outcome of chronic phase chronic myeloid leukemia patients on imatinib first-line. CML, OS
43  2019 Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial. OS, TTFields
44  2019 Induction of Peripheral Effector CD8 T-cell Proliferation by Combination of Paclitaxel, Carboplatin, and Bevacizumab in Non-small Cell Lung Cancer Patients. CTLA-4, NSCLC, OS, PCB, PD
45  2019 Lymph node ratio in inguinal lymphadenectomy for squamous cell vulvar cancer: Results from the AGO-CaRE-1 study. LN, LNR
46  2019 Molecular features and clinical outcomes in surgically treated low-grade diffuse gliomas in patients over the age of 60. OS
47  2019 Morbidity after surgical management of cervical cancer in low and middle income countries: A systematic review and meta-analysis. LMIC, OS
48  2019 Negative Effect of Immediate Sunitinib Interruption on Survival in Patients With Metastatic Renal Cell Carcinoma. HR, mRCC, TI
49  2019 Patterns of practice and pharmacoeconomic analysis of the management of patients with metastatic renal cell carcinoma (mRCC) in Greece--the CRISIS study. A retrospective analysis by the Hellenic Genitourinary Cancer Group (HGUCG). CI, HGUCG, mRCC, OS, SD
50  2019 Phase 1 study of EUS-guided photodynamic therapy for locally advanced pancreatic cancer. LAPC, OS, PDT
51  2019 Phase I Dose Escalation Study with Expansion Cohort of the Addition of Nab-Paclitaxel to Capecitabine and Oxaliplatin (CapOx) as First-Line Treatment of Metastatic Esophagogastric Adenocarcinoma (ACTION Study). CapOx, MTD
52  2019 Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma. DLTs, RRMM
53  2019 Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation. aGVHD, cGVHD, GVHD, MUD, NRM, PTCy, RIC
54  2019 Post-treatment Glasgow Prognostic Score Predicts Efficacy in Advanced Non-small-cell Lung Cancer Treated With Anti-PD1. GPS, NSCLC, PD1
55  2019 Predictors of cisplatin-induced ototoxicity and survival in chemoradiation treated head and neck cancer patients. HNSCC, OS
56  2019 Pretreatment Neutrophil-to-Lymphocyte Ratio Predicts Survival After TAS-102 Treatment of Patients With Metastatic Colorectal Cancer. HR, mCRC, NLR
57  2019 Prognostic significance of circulating tumor cells (CTCs) in Egyptian non-metastatic colorectal cancer patients: A comparative study for four different techniques of detection (Flowcytometry, CellSearch, Quantitative Real-time PCR and Cytomorphology). BBD, CS, CTCs, FCM, NC
58  2019 Prognostic value of subventricular zone involvement in relation to tumor volumes defined by fused MRI and O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET imaging in glioblastoma multiforme. dtp, FET, GBM, KPS, OS, PET, SVZ
59  2019 Quantitative evaluation of liver metastases density on computed tomography: A new tool to evaluate early response to bevacizumab-containing chemotherapy. CRLM, CT, OS, RECIST, TTLD
60  2019 Serum Prognostic Factors of Androgen-deprivation Therapy Among Japanese Men With De Novo Metastatic Prostate Cancer. CI, HR
61  2019 Standard of care vs reduced-dose chemoradiation after induction chemotherapy in HPV+ oropharyngeal carcinoma patients: The Quarterback trial. HPVOPC, HR, IC, OS, rdCRT, sdCRT
62  2019 Stereotactic body radiotherapy with adjuvant systemic therapy for early-stage non-small cell lung carcinoma: A multi-institutional analysis. NSCLC, OS, RDF, SBRT, ST
63  2019 The preliminary results of proton and carbon ion therapy for chordoma and chondrosarcoma of the skull base and cervical spine. LC, OS
64  2019 The value of pretreatment serum butyrylcholinesterase level as anovel prognostic biomarker in patients with cervical cancer treated with primary (chemo-)radiation therapy. BChE, OS
65  2019 Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study. ECOG, ICI, NSCLC, ORR
66  2019 Ventricular-Subventricular Zone Contact by Glioblastoma is Not Associated with Molecular Signatures in Bulk Tumor Data. HRs
67  2019 ypT0N+ status in oesophageal cancer patients: Location of residualmetastatic lymph nodes with regard to the neoadjuvant radiation field. OS
68  2018 A Pathological Study Using 2014 WHO Criteria Reveals Poor Prognosis of Grade 3 Ovarian Endometrioid Carcinomas. EC, HGSC
69  2018 Advanced high-grade serous ovarian cancer: inverse association of KLK13 and KLK14 mRNA levels in tumor tissue and patients' prognosis. HR, OS
70  2018 Are There Differences in Toxicity and Efficacy between Various Bacillus Calmette-Guerin Strains in Bladder Cancer Patients? Analysis of 844 Patients. BCG, OS
71  2018 Chemotherapy Plus Bevacizumab as Neoadjuvant or Conversion Treatment in Patients with Colorectal Liver Metastases. CLM, OS, PR, RFS
72  2018 DEPDC5 deficiency contributes to resistance to leucine starvation via p62 accumulation in hepatocellular carcinoma. DEPDC5-KO, DEPDC5-WT, HCC, OS, ROS
73  2018 Do differences in medical comorbidities and treatment impact racial disparities in epithelial ovarian cancer? CCC, CCI, NCI, OS
74  2018 Haploidentical Transplants with Post-Transplant Cyclophosphamide for Relapsed or Refractory Hodgkin Lymphoma: The Role of Comorbidity Index and Pretransplant Positron Emission Tomography. CI, FDG-PET, GRFS, GVHD, HCT, HCT-CI, HL, HR, NMA, PTCy
75  2018 High UDG and BRCA1 expression is associated with adverse outcome in patients with pemetrexed treated non-small cell lung Cancer. NSCLC, OS, UDG
76  2018 Identification of Driver Genes and Key Pathways of Ependymoma. DEGs, EPN, GO, KEGG, MMR, PPI
77  2018 Long-term Effects of Growth Hormone Replacement Therapy in Childhood-onset Craniopharyngioma: Results of the German Craniopharyngioma Registry (HIT-Endo). BMI, contGH, CP, GH, OS
78  2018 Long-term outcomes and recurrence pattern of 18F-FDG PET-CT complete metabolic response in the first-line treatment of metastatic colorectal cancer: a lesion-based and patient-based analysis. CMR, CR, mCRC, OS, PMD, RECIST, ROC
79  2018 Metric substage according to micro and extensive lamina propria invasion improves prognostics in T1 bladder cancer. CSS, HR, MM, T1BC, TUR
80  2018 Nucleic acid based risk assessment and staging for clinical practice in multiple myeloma. CA, FISH, LDH, MLPA, MM, OS, qRT-PCR, R-ISS
81  2018 Number of Resected Lymph Nodes and Survival of Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Receiving Preoperative Chemoradiotherapy. CRT, ESCC, LN
82  2018 Obesity negatively impacts outcome in elderly female patients with aggressive B-cell lymphomas treated with R-CHOP: results from prospective trials of the German high grade non-Hodgkin's lymphoma trial group. BMI, HR, OS
83  2018 Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial. AEs, HR, OS
84  2018 Outcome analysis of Phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancer. NSCLC
85  2018 Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. allo-SCT, B-NHL, DELs, DHLs, OS, SCT
86  2018 Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease. CTCAE, hPFS, M-PHP, UM
87  2018 Percutaneous irreversible electroporation with systemic treatment for locally advanced pancreatic adenocarcinoma. IRE, LAPC, OS
88  2018 Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping. mCRC
89  2018 Practice Patterns and Outcomes for Pemetrexed Plus Platinum Doublet as Neoadjuvant Chemotherapy in Adenocarcinomas of Lung: Looking Beyond the Usual Paradigm. NACT, NSCLC
90  2018 Predicting Oncologic Outcomes in Renal Cell Carcinoma After Surgery. ccRCC, chrRCC, CSS, papRCC
91  2018 Prediction of survival with multi-scale radiomic analysis in glioblastoma patients. FLAIR, GBM, HR, LoG, OS, RF, T1WI
92  2018 Predictive Value of Early Skin Rash in Cetuximab-Based Therapy of Advanced Biliary Tract Cancer. AEs, BTC, ORR, OS
93  2018 Preoperative CA-125 Value as a Predictive Factor for Postoperative Outcome in First Relapse of Platinum-sensitive Serous Ovarian Cancer. CA125, SCS
94  2018 Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI. OS, rCBV
95  2018 Prognostic Significance of omental Disease and the Role of Omental Sampling in Patients With Uterine Carcinosarcoma. OS
96  2018 Prognostic significance of tumor budding in muscle invasive urothelial carcinomas of the bladder. LVI, MIBC, OS, PNI
97  2018 Prognostic value of early 18F-FDG PET scanning evaluation in immunocompetent primary CNS lymphoma patients. CR, CRu, DLBCL, ETR, OS, PCNSL, PET, RMT
98  2018 Prognostic value of volume-based metabolic parameters of 18F-FDG PET/CT in ovarian cancer: a systematic review and meta-analysis. HRs, MTV, OS, TLG
99  2018 Prognostic value of [18F]FDG-PET/CT in multiple myeloma patients before and after allogeneic hematopoietic cell transplantation. allo-HCT, IMWG, MM, OS, PET/CT
100  2018 Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential. HAI, OS, SYS